SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q2 FY23 results · Jul–Sep 2022
SMS Pharmaceuticals reported revenue from operations of ₹159.43 crore (down 8.7% from Q2 FY22) and net loss of ₹2.01 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 159.43 | 174.70 | −8.7% | 64.39 | +147.6% |
| Other income | 0.61 | 1.36 | −54.7% | 0.80 | −23.4% |
| Total income | 160.05 | 176.06 | −9.1% | 65.19 | +145.5% |
| Profit before share of associates & JVs and tax | 0.84 | 35.24 | −97.6% | (12.79) | Turned profit |
| Share of profit/(loss) of associates & JVs | (2.74) | (1.99) | (2.58) | ||
| Net profit for the period | (2.01) | 23.03 | Turned loss | (12.77) | Loss narrowed |
| EPS, basic (₹) | (0.24) | 2.72 | Turned loss | (1.51) | Loss narrowed |
| Net margin (%) | -1.3 | 13.2 | -19.8 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 159.43 | 174.70 | −8.7% | 64.39 | +147.6% |
| Other income | 0.61 | 1.36 | −54.7% | 0.80 | −23.4% |
| Total income | 160.05 | 176.06 | −9.1% | 65.19 | +145.5% |
| Profit before tax | 0.90 | 35.50 | −97.5% | (12.41) | Turned profit |
| Net profit for the period | 0.79 | 25.27 | −96.9% | (9.81) | Turned profit |
| EPS, basic (₹) | 0.09 | 2.99 | −97.0% | (1.16) | Turned profit |
| Net margin (%) | 0.5 | 14.5 | -15.2 |
Consolidated
- Filed with BSE
- 24 Nov 2022, 11:09 IST
- Board meeting
- 12 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Nov 2022, 11:09 IST
- Board meeting
- 12 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE